Suppr超能文献

PI3K的激活与肾细胞癌患者生存率降低相关。

Activation of PI3K is associated with reduced survival in renal cell carcinoma.

作者信息

Merseburger Axel S, Hennenlotter Joerg, Kuehs Ursula, Simon Perikles, Kruck Stephan, Koch Eva, Stenzl Arnulf, Kuczyk Markus A

机构信息

Department of Urology, Eberhard Karls University Tübingen, Tübingen, Germany.

出版信息

Urol Int. 2008;80(4):372-7. doi: 10.1159/000132694. Epub 2008 Jun 27.

Abstract

OBJECTIVES

The epidermal growth factor receptor- (EGFR) activated phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB/Akt) pathway is associated with tumorigenesis and progression. The aims of the present study were to determine the expression patterns of Akt pathway parameters PI3K, phosphatase and tensin homolog (PTEN), phosphor-Akt (p-Akt) and their combination, for their possible prognostic value in renal cell carcinoma (RCC). PTEN dephosphorylates the liquid product of PI3K.

METHODS

Tumor samples from 176 RCC patients were investigated for PTEN, p-Akt and PI3K expression by immunohistochemistry. Expression levels were correlated to clinical variables and postoperative outcome by uni- and multivariate statistical analysis.

RESULTS

The various expression levels within the tumor samples were independent of histological grade and tumor stage, due to different levels of activation of the PI3K/p-Akt pathway. The activation of PI3K protein was found to be significantly associated with reduced survival times (p = 0.0304, multivariate analysis). Analysis of combined biomarker expressions showed that decreased long-term survival was correlated with PTEN low/p-Akt high expression (p < 0.05).

CONCLUSIONS

Activation of the PI3K pathway is significantly associated with adverse clinical outcome in RCC. Analysis of biomarker combinations might identify high-risk patients and a subsequent need to adapt treatment modalities. Molecular pathways regulating PI3K activation appear to be promising targets for drug development in the clinical management of RCC patients.

摘要

目的

表皮生长因子受体(EGFR)激活的磷脂酰肌醇3激酶(PI3K)/蛋白激酶B(PKB/Akt)信号通路与肿瘤的发生和进展相关。本研究旨在确定Akt信号通路参数PI3K、磷酸酶和张力蛋白同源物(PTEN)、磷酸化Akt(p-Akt)及其组合的表达模式,以探讨其在肾细胞癌(RCC)中的潜在预后价值。PTEN可使PI3K的产物去磷酸化。

方法

采用免疫组织化学法检测176例RCC患者肿瘤样本中PTEN、p-Akt和PI3K的表达。通过单因素和多因素统计分析,将表达水平与临床变量和术后结果进行关联。

结果

由于PI3K/p-Akt信号通路的激活水平不同,肿瘤样本中的各种表达水平与组织学分级和肿瘤分期无关。发现PI3K蛋白的激活与生存时间缩短显著相关(多因素分析,p = 0.0304)。联合生物标志物表达分析表明,长期生存率降低与PTEN低表达/p-Akt高表达相关(p < 0.05)。

结论

PI3K信号通路的激活与RCC不良临床预后显著相关。生物标志物组合分析可能有助于识别高危患者,并确定后续调整治疗方式的必要性。调节PI3K激活的分子通路似乎是RCC患者临床治疗中药物研发的有前景的靶点。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验